• Eikon Therapeutics presented early-stage cancer trial results for EIK1003, EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress.
• EIK1003 showed antitumor activity alone and in combinations; the paclitaxel combination’s safety profile was consistent with the chemotherapy’s known toxicities.
• EIK1004 showed tumor responses with limited severe blood-related side effects; initial results from a planned docetaxel combination arm are expected in late 2027.
• EIK1005 showed disease stabilization alone and a partial response in one pembrolizumab combination participant; its drug-exposure profile supported weekly dosing.
• Additional EIK1005 combination results are expected in the first half of 2027, with complete monotherapy results due in the second half.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230915PRIMZONEFULLFEED9851797) on October 23, 2026, and is solely responsible for the information contained therein.